Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Indomethacin
A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
Year introduced: 1966 (1964)
beta-cyclodextrin, indomethacin drug combination [Supplementary Concept]
chinoin-137 consists of indomethacin & beta-cyclodextrin in [1:2] molar ratio
Date introduced: January 11, 1982
4'-(bromoacetamido)-benzyl-indomethacin [Supplementary Concept]
bromoacetamido-analog of indomethacin; structure given in first source
Date introduced: May 26, 1998
N-succinimidyl-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate [Supplementary Concept]
inactivates prostaglandin endoperoxide synthase; structure given in first source
Date introduced: April 10, 1993
1-(4-chlorobenzoyl)-3-(2-(1H-imidazol-1-yl)-2-oxoethyl)-5-methoxy-2-methyl-1H-indole [Supplementary Concept]
indomethacin ethoxycarbonylmethyl ester [Supplementary Concept]
Date introduced: August 3, 1983
arginine, indomethacin, isamfazone drug combination [Supplementary Concept]
Date introduced: January 23, 1982
phospho-tyrosol-indomethacin [Supplementary Concept]
has antineoplastic activity; structure in first source
Date introduced: May 15, 2013
indomethacin ethyl ester [Supplementary Concept]
structure in first source
Date introduced: January 25, 2006
indomethacin phenethylamide [Supplementary Concept]
a cyclooxygenase-2 inhibitor; structure in first source
Date introduced: September 10, 2004
indomethacin morpholinylamide [Supplementary Concept]
an inverse agonist of the cannabinoid CB2 receptor
Date introduced: March 8, 2003
indomethacin triethylene ester [Supplementary Concept]
structure given in first source
Date introduced: March 4, 1997
indomethacin farnesil [Supplementary Concept]
Date introduced: July 17, 1989
5-hydroxyindomethacin [Supplementary Concept]
metabolite of indomethacin
Date introduced: June 24, 1982
5-methoxy-methylindoleacetic acid [Supplementary Concept]
Date introduced: July 24, 1981
acemetacin [Supplementary Concept]
Date introduced: October 28, 1980
VUFB 12018 [Supplementary Concept]
structure
Date introduced: January 1, 1979
N-acetylcysteine-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 4-(nitrooxy)butyl ester [Supplementary Concept]
a nitric oxide donor with antitrypanosomal activity; structure in first source
Date introduced: April 12, 2015